MedTrace Logo

Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

NCT00350727 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2013-04-19

Study results available
· View outcomes & findings →

Summary

This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.

Conditions

Interventions

DRUG

pazopanib

Pazopanib is a novel compound being developed for the treatment of various cancers.

DRUG

lapatinib

Lapatinib is a novel compound being developed for the treatment of various cancers.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00350727 on ClinicalTrials.gov